Skip to main content

Specializing in large-scale hiPSC projects.


The Paul Burridge Lab

The Burridge lab works in the field of pharmacogenomics (precision medicine), cardio-oncology, cardiovascular disease modeling, regenerative medicine,  cancer, and cultivated meat, using induced pluripotent stem cells (iPSCs) as our model. We specialize in large-scale hiPSC projects that required reprogramming, sequencing, editing, differentiating and phenotyping hundreds of hiPSC lines. 

We are responsible for a number of firsts including: the first directed cardiac differentiation protocol (Burridge et al., 2006), the first non-integrating reprogramming of blood to iPSC (Burridge et al., 2011), the first chemically defined differentiation protocol (Burridge et al., 2014), the first demonstration that doxorubicin-induced cardiotoxicity is a genomic disease (Burridge et al., 2016), the first cost-effective method of culturing iPSC (Kuo et al., 2020), and most recently, the genomic basis of predispostion to doxorubicin-induced cardiotoxicity (Magdy et al., 2021 and 2022).

Our Work

Our research program is focused on using induced pluripotent stem cells (iPSC) in pharmacogenomics, disease modeling and regenerative medicine. Applying a combination of hiPSC culture, tissue engineering, sequencing, high-throughput assays and drug screens, we can establish the genetic cause of a patient's specific drug response and use this information to discover new drugs.

Review Current Projects  Read Our Publications

Our Team

Meet the Burridge lab team members. We welcome requests for information about our work and collaboration opportunities.

Meet Our Lab Members  Contact Us

Explore the resources we rely on to do our work.See Resources